ABCG2 and renal cell adenocarcinoma: Overexpression of breast cancer resistance protein BCRP/ABCG2, which is posttranscriptionally suppressed by miR-212-3p and miR-132-3p, is associated with superior response to sunitinib treatment in RCC patients (Reustle et al., 2018).